Welcome back to the Psychedelic Invest week in review. Here are the stories that moved the psychedelic sector during the week of December 29, 2025 – January 4, 2026 — from clinical readouts to regulatory shifts and the capital flowing through the space.
Cybin Inc. (CYBN): Cybin launches at-the-market equity program of up to US$100 million
Cybin initiated an at-the-market equity program allowing it to sell up to US$100 million of common shares from treasury at prevailing prices, managed by Cantor Fitzgerald and established via a prospectus supplement dated December 30, 2025. The program gives the company flexible access to capital to fund its late-stage CYB003 and CYB004 programs just ahead of its Nasdaq listing transition and Helus Pharma rebrand; some coverage noted the stock dipped on the dilution potential.
Source: businesswire.com
AtaiBeckley Inc. (ATAI): AtaiBeckley completes redomiciliation from the Netherlands to Delaware
AtaiBeckley completed its corporate redomiciliation to the United States following the close of Nasdaq trading on December 30, 2025, exchanging all outstanding Atai Beckley N.V. ordinary shares one-for-one for shares of Delaware-incorporated AtaiBeckley Inc. Approved by roughly 99% of votes at the company's November EGM, the shares continue trading on Nasdaq under 'ATAI,' with headquarters in New York, simplifying the corporate structure for U.S. investors.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.